(Edgar Glimpses Via Acquire Media NewsEdge) Item 1.01 Entry Into a Material Definitive Agreement.
On July 2, 2014, Techne Corporation, a Minnesota corporation (the "Company"),
entered into a Unit Purchase Agreement (the "Agreement") with Novus Holdings,
LLC, a Delaware limited liability company ("Novus"), the members of Novus, and
Mainsail Partners II L.P., as the Members' Representative. Pursuant to the terms
of the Agreement, on July 2, 2014, the Company acquired all of the issued and
outstanding equity interests of Novus (the "Acquisition").
The Company paid $60 million for the acquisition of Novus, which amount has been
distributed to the members of Novus after payment of Novus' debt, transaction
expenses, and obligations related to change of control arrangements. Of the $60
million purchase price, $6 million will be held in escrow for 15 months to
secure the indemnity obligations of the members of Novus set forth in the
This description of the material terms of the Agreement does not purport to be
complete and is qualified in its entirety by reference to the full text of the
Agreement, which will be filed as an exhibit to the Company's Annual Report on
Form 10-K for the fiscal year ending June 30, 2014.
A copy of the press release announcing the investment is filed herewith as
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
In connection with the Acquisition, on July 2, 2014, the Company appointed David
Eansor, 53, as Senior Vice President, Novus Biologicals.
Prior to the Acquisition, Mr. Eansor was the Senior Vice President of Corporate
Development of Novus Biologicals, LLC, a Delaware limited liability company and
a subsidiary of Novus ("Biologicals"). He joined Biologicals in January of 2013.
Following the acquisition of Novus, and indirectly Biologicals, by the Company,
Mr. Eansor's primary responsibilities will be the day-to-day management of
Prior to joining Biologicals, Mr. Eansor was the President of the Bioscience
Division of Thermo Fisher Scientific. The Bioscience Division includes the Life
Science Research (LSR) businesses, the Bioprocess Production business and the
Global Chemicals business. Mr. Eansor was promoted to Division President in
early 2010 after 5 years as President of Thermo Fisher's Life Science Research
business which included the Genomics (legacy Dharmacon, Abgene and Molecular
Bioreagents (aka Pierce Milwaukee)) businesses as well as three businesses
acquired by the Genomics group during David's tenure (Open Biosystems, Finnzymes
and Fermentas), Proteomics (legacy Pierce Rockford and the acquired Affinity
Bioreagents) and Cellomics.
Mr. Eansor has a BSc in Chemistry from University of Western Ontario, a
Bachelors of Commerce in General Business and Economics, and an MBA from the
University of Windsor, Ontario, Canada.
On July 2, 2014, Mr. Eansor entered into an employment agreement with the
Company (the "Employment Agreement"). The Employment Agreement has an initial
term of employment beginning June 2, 2014 and continuing for three years. The
Employment Agreement provides for an initial annual base salary of $325,000.
Mr. Eansor will receive reimbursement of certain business expenses in connection
with his service to the Company. Mr. Eansor is also eligible for paid time off,
participation in any other employee benefit plans generally available to the
Company's employees, and certain other benefits as set forth in the Employment
Agreement. The Employment Agreement contains the Company's customary
non-competition, confidentiality, and assignment of intellectual property terms.
The Employment Agreement grants Mr. Eansor 5,000 Restricted Stock Units in the
Company that will vest over a period over three years. Mr. Eansor is also
eligible to participate in the Company's Management Incentive Plan.
The Employment Agreement may be terminated at any time by either party upon
written notice. If the Employment Agreement is terminated in certain
circumstances, such as by the Company without Cause, by the Company following a
Change in Control, or by Mr. Eansor for Good Reason (each such capitalized term
as defined in the Employment Agreement), the Company will be required to pay
severance to Mr. Eansor in an amount equal to one year of his then-current base
salary. Any severance paid to Mr. Eansor will be paid in exchange for
Mr. Eansor's release of claims against the Company.
There is not currently, nor has there been in the past, any transaction with the
Company or any of its subsidiaries or affiliates in which Mr. Eansor has or had
a direct or an indirect material interest.
This description of the material terms of the Employment Agreement does not
purport to be complete and is qualified in its entirety by reference to the full
text of the Employment Agreement, which will be filed as an exhibit to the
Company's Annual Report on Form 10-K for the fiscal year ending June 30, 2014.
Item 9.01 Financial Statements and Exhibits
99.1 Press Release, dated July 2, 2014.